Treatment with the CC chemokine-binding protein Evasin-4 improves post-infarction myocardial injury and survival in mice
- 1 January 2013
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 110 (10), 807-825
- https://doi.org/10.1160/th13-04-0297
Abstract
Chemokines trigger leukocyte trafficking and are implicated in cardiovascular disease pathophysiology. Chemokine-binding proteins, called “Evasins” have been shown to inhibit both CC and CXC chemokinemediated bioactivities. Here, we investigated whether treatment with Evasin-3 (CXC chemokine inhibitor) and Evasin-4 (CC chemokine inhibitor) could influence post-infarction myocardial injury and remodelling. C57Bl/6 mice were submitted in vivo to left coronary artery permanent ligature and followed up for different times (up to 21 days). After coronary occlusion, three intraperitoneal injections of 10 μg Evasin-3, 1 μg Evasin-4 or equal volume of vehicle (PBS) were performed at 5 minutes, 24 hours (h) and 48 h after ischaemia onset. Both anti-chemokine treatments were associated with the beneficial reduction in infarct size as compared to controls. This effect was accompanied by a decrease in post-infarction myocardial leukocyte infiltration, reactive oxygen species release, and circulating levels of CXCL1 and CCL2. Treatment with Evasin-4 induced a more potent effect, abrogating the inflammation already at one day after ischaemia onset. At days 1 and 21 after ischaemia onset, both anti-chemokine treatments failed to significantly improve cardiac function, remodelling and scar formation. At 21-day follow-up, mouse survival was exclusively improved by Evasin-4 treatment when compared to control vehicle. In conclusion, we showed that the selective inhibition of CC chemokines (i.e. CCL5) with Evasin-4 reduced cardiac injury/inflammation and improved survival. Despite the inhibition of CXC chemokine bioactivities, Evasin-3 did not affect mouse survival. Therefore, early inhibition of CC chemokines might represent a promising therapeutic approach to reduce the development of post-infarction heart failure in mice. * These authors contributed equally as first authors. # These authors contributed equally as last authors.This publication has 30 references indexed in Scilit:
- Leukocyte Behavior in Atherosclerosis, Myocardial Infarction, and Heart FailureScience, 2013
- Longitudinal Study of Cardiac Remodelling in Rabbits Following InfarctionCanadian Journal of Cardiology, 2012
- Persistent dysfunction of viable myocardium after revascularization in chronic ischaemic heart disease: implications for dobutamine stress echocardiography with longitudinal systolic strain and strain rate measurementsEuropean Heart Journal – Cardiovascular Imaging, 2012
- Double-Edged Role of the CXCL12/CXCR4 Axis in Experimental Myocardial InfarctionJournal of the American College of Cardiology, 2011
- CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in miceEuropean Heart Journal, 2011
- Single Administration of the CXC Chemokine-Binding Protein Evasin-3 During Ischemia Prevents Myocardial Reperfusion Injury in MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injuryThrombosis and Haemostasis, 2009
- Ticks produce highly selective chemokine binding proteins with antiinflammatory activityThe Journal of Experimental Medicine, 2008
- Molecular Cloning and Characterization of a Highly Selective Chemokine-binding Protein from the Tick Rhipicephalus sanguineusPublished by Elsevier BV ,2007
- The inflammatory response in myocardial infarctionCardiovascular Research, 2002